PDCD1 and melanoma: Finally, the surface markers CD69 and PD-1 were also found to be expressed on CD4+ T cells in metastatic tumors but the prognostic value of assessing these markers using immunohistochemistry or in situ IF remains to be demonstrated in melanoma (69).